Q3 2025 Aurora Cannabis Inc Earnings Call Transcript
Key Points
- Aurora Cannabis Inc (ACB) reported a record third quarter for medical cannabis revenue, net income, adjusted EBITDA, and free cash flow.
- Overall net revenue grew 37%, driven by a 51% year-over-year growth in global medical cannabis.
- International revenue increased 112%, surpassing Canadian medical cannabis revenue for the second consecutive quarter.
- The company achieved a record adjusted gross margin of 65% and a record adjusted EBITDA of $23.1 million.
- Aurora Cannabis Inc (ACB) ended the quarter with $180.2 million in cash and cash equivalents and no cannabis business debt.
- Consumer cannabis net revenue decreased to $9.9 million from $11.6 million in the year-ago period.
- Adjusted gross margins for consumer cannabis fell to 26% from 29% due to changes in sales mix.
- The Canadian recreational cannabis segment saw a decline in revenue, highlighting challenges in extracting value from high-quality products.
- The company faces complexities in supplying international markets due to varying regulatory challenges.
- Bevo's plant propagation business, while growing, is subject to seasonal revenue fluctuations.
Greetings, and welcome to the Aurora Cannabis Inc third quarter 2025 results conference call. (Operator Instructions) This conference call is being recorded today, Wednesday, February 5, 2025.
I would now like to turn the conference over to your host, Kevin Niland, Director of Strategic Finance and Investor Relations. Please go ahead.
Hello, everyone, and thank you for joining us. With me on the line with me are Miguel Martin, Executive Chairman and CEO; Simona King, CFO. This morning, we filed our financials for the third quarter 2025, period ending December 31, 2024, and issued a news release containing our quarterly results. This news release, along with our financial statements and NDA are available on our IR website and can also be accessed via SEDAR+ and EDGAR.
In today's conference call, this is a reminder that certain matters to constitute forward-looking statements and are subject to risks and uncertainties related to our future financial or
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
